DeepMed Research

UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer

Completed

Conditions: Breast Neoplasm Female

Interventions: Diagnostic Test: IHC4 score

First Posted Date: 2020-01-29

Last Posted Date: 2023-11-18

Lead Sponsor: UNICANCER

Target Recruit Count: 155

Registration Number: NCT04246606

Locations: 🇫🇷
Centre Antoine Lacassagne, Nice, France

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Phase 3

Recruiting

Conditions: Prostate Cancer

Interventions: Radiation: Salvage radiotherapy (SRT)
Drug: Apalutamide
Drug: Luteinising Hormone Releasing Hormone agonist (LHRHa)

First Posted Date: 2019-11-29

Last Posted Date: 2024-04-09

Lead Sponsor: UNICANCER

Target Recruit Count: 490

Registration Number: NCT04181203

Locations: 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇫🇷
Centre Paul STRAUSS, Strasbourg, France
🇫🇷
Centre Georges François LECLERC, Dijon, France

and more 11 locations

Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

Phase 3

Recruiting

Conditions: Cancer Metastatic

Interventions: Drug: Letrozole 2.5mg
Drug: Paclitaxel injection
Drug: Anastrozole 1mg
Drug: Capecitabine tablets
Drug: Fulvestrant Prefilled Syringe
Drug: Abemaciclib

First Posted Date: 2019-11-08

Last Posted Date: 2024-01-22

Lead Sponsor: UNICANCER

Target Recruit Count: 180

Registration Number: NCT04158362

Locations: 🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite, France
🇫🇷
Centre Eugène Marquis, Rennes, France

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

Phase 2

Active, not recruiting

Conditions: Breast Tumors

Interventions: Drug: DS-8201a

First Posted Date: 2019-10-21

Last Posted Date: 2024-12-13

Lead Sponsor: UNICANCER

Target Recruit Count: 186

Registration Number: NCT04132960

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre François Baclesse, Caen, France

and more 12 locations

Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

Phase 3

Recruiting

Conditions: Oligometastatic Hormone Sensitive Prostate Cancer

Interventions: Radiation: Stereotactic Body Radiotherapy (SBRT) + Standard of care
Drug: Standard of care

First Posted Date: 2019-10-03

Last Posted Date: 2024-04-29

Lead Sponsor: UNICANCER

Target Recruit Count: 550

Registration Number: NCT04115007

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Centre d'oncologie - Clinique Pasteur, Brest, France

and more 32 locations

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Phase 2

Active, not recruiting

Conditions: BRAF V600 Mutation
Malignant Melanoma
Brain Metastases

Interventions: Radiation: Stereotaxic radiosurgery (SRS)
Drug: Binimetinib Oral Tablet
Drug: Pembrolizumab
Drug: Encorafenib Oral Capsule

First Posted Date: 2019-08-29

Last Posted Date: 2024-06-03

Lead Sponsor: UNICANCER

Target Recruit Count: 10

Registration Number: NCT04074096

Locations: 🇫🇷
APHP - Hôpital Avicenne, Bobigny, France
🇫🇷
CHU de Caen, Caen, France
🇫🇷
CHU de Bordeaux - Hôpital Saint André, Bordeaux, France

and more 18 locations

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Phase 2

Active, not recruiting

Conditions: ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

Interventions: Drug: Durvalumab
Drug: Olaparib
Drug: Fulvestrant

First Posted Date: 2019-08-12

Last Posted Date: 2025-03-12

Lead Sponsor: UNICANCER

Target Recruit Count: 172

Registration Number: NCT04053322

Locations: 🇫🇷
Centre Henri-Becquerel, Rouen, France
🇫🇷
Institut de Cancerologie de Montpellier, Montpellier, France

Impact of Immunoscore Colon Test on Adjuvant Therapeutic Strategy in Non-Metastatic Colon Cancer

Not Applicable

Withdrawn

Conditions: Colonic Neoplasms

Interventions: Diagnostic Test: Immunoscore Colon Test

First Posted Date: 2019-05-10

Last Posted Date: 2019-08-30

Lead Sponsor: UNICANCER

Registration Number: NCT03946033

Locations: 🇫🇷
Hôpital Simone Veil, Blois, France
🇫🇷
CHU de Dijon, Dijon, France
🇫🇷
Institut Régional du Cancer de Montpellier, Montpellier, France

and more 18 locations

Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

Phase 3

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Gemcitabine
Drug: Paclitaxel

First Posted Date: 2019-05-09

Last Posted Date: 2023-11-08

Lead Sponsor: UNICANCER

Target Recruit Count: 211

Registration Number: NCT03943667

Locations: 🇫🇷
Hôpital Européen de Marseille, Marseille, France
🇫🇷
Hôpital Pitié-Salpétrière, Paris, France
🇫🇷
Hospices civils de Lyon, Lyon, France

and more 23 locations

Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast

Not Applicable

Active, not recruiting

Conditions: Low Risk DCIS
DCIS
Breast Cancer
Breast Conserving Surgery
Radiotherapy Omission

Interventions: Other: No Radiotherapy
Radiation: Radiotherapy

First Posted Date: 2019-03-18

Last Posted Date: 2024-11-27

Lead Sponsor: UNICANCER

Target Recruit Count: 295

Registration Number: NCT03878342

Locations: 🇫🇷
Institut de Cancérologie de l'Ouest -Site Paul Papin, Angers, France
🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷
Centre d'Oncologie et de Radiothérapie du Pays Basque, Bayonne, France

and more 34 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy